180 Wealth Advisors’s Novavax NVAX Stock Holding History

180 Wealth Advisors’s Portfolio NVAX Stock Details NVAX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	–	Sell	-1,000	Closed	-$38K	–	270
2018 Q4	$38K	Hold	1,000	–	–	0.02%	251
2018 Q3	$38K	Buy	+1,000	New	+$28.2K	0.02%	251

Other funds holding NVAX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

180 Wealth Advisors's NVAX Position: Q1 2019 in Review

180 Wealth Advisors sold out of Novavax (NVAX) in Q1 2019, closing a stake of 1,000 shares — an estimated $38K sold.

180 Wealth Advisors first reported a position in NVAX in Q3 2018 and held it in 2 quarters. The position peaked at $38K in Q4 2018. 140 funds tracked by Wall St. Rank hold NVAX as of Q1 2019.

180 Wealth Advisors reported no remaining Novavax position as of Q1 2019 after selling out during the quarter.
180 Wealth Advisors sold 1,000 Novavax shares in Q1 2019, an estimated $38K.
180 Wealth Advisors first reported a position in Novavax in Q3 2018 and held it in 2 quarters.
180 Wealth Advisors's Novavax position peaked at $38K in Q4 2018.
140 funds tracked by Wall St. Rank held Novavax as of Q1 2019.

Based on 180 Wealth Advisors's 13F filing for Q1 2019, filed 14 May 2019.